Literature DB >> 21214563

Brain pathology in Niemann Pick disease type A: insights from the acid sphingomyelinase knockout mice.

Maria Dolores Ledesma1, Alessandro Prinetti, Sandro Sonnino, Edward H Schuchman.   

Abstract

Severe neurological involvement characterizes Niemann Pick disease (NPD) type A, an inherited disorder caused by loss of function mutations in the gene encoding acid sphingomyelinase (ASM). Mice lacking ASM, which mimic NPD type A, have provided important insights into the aberrant brain phenotypes induced by ASM deficiency. For example, lipid alterations, including the accumulation of sphingolipids, affect the membranes of different subcellular compartments of neurons and glial cells, leading to anomalies in signalling pathways, neuronal polarization, calcium homeostasis, synaptic plasticity, myelin production or immune response. These findings contribute to our understanding of the overall role of sphingolipids and their metabolic enzymes in brain physiology, and pave the way to design and test new therapeutic strategies for type A NPD and other neurodegenerative disorders. Some of these have already been tested in mice lacking ASM with promising results.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21214563      PMCID: PMC3059095          DOI: 10.1111/j.1471-4159.2010.07034.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  70 in total

1.  Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development.

Authors:  S L Schissel; X Jiang; J Tweedie-Hardman; T Jeong; E H Camejo; J Najib; J H Rapp; K J Williams; I Tabas
Journal:  J Biol Chem       Date:  1998-01-30       Impact factor: 5.157

2.  Ganglioside alterations in the central and peripheral nervous systems of patients with Creutzfeldt-Jakob disease.

Authors:  Y Ohtani; Y Tamai; Y Ohnuki; S Miura
Journal:  Neurodegeneration       Date:  1996-12

3.  Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models.

Authors:  Iwan Jones; Xingxuan He; Fourogh Katouzian; Peter I Darroch; Edward H Schuchman
Journal:  Mol Genet Metab       Date:  2008-09-23       Impact factor: 4.797

4.  Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A.

Authors:  Barbara Buccinnà; Marco Piccinini; Alessandro Prinetti; Federica Scandroglio; Simona Prioni; Manuela Valsecchi; Barbara Votta; Silvia Grifoni; Elisa Lupino; Cristina Ramondetti; Edward H Schuchman; Maria Teresa Giordana; Sandro Sonnino; Maria Teresa Rinaudo
Journal:  J Neurochem       Date:  2009-02-02       Impact factor: 5.372

5.  Lipid content of brain, brain membrane lipid domains, and neurons from acid sphingomyelinase deficient mice.

Authors:  Federica Scandroglio; Jagadish Kummetha Venkata; Nicoletta Loberto; Simona Prioni; Edward H Schuchman; Vanna Chigorno; Alessandro Prinetti; Sandro Sonnino
Journal:  J Neurochem       Date:  2008-09-18       Impact factor: 5.372

Review 6.  Ceramide-enriched membrane domains--structure and function.

Authors:  Yang Zhang; Xiang Li; Katrin Anne Becker; Erich Gulbins
Journal:  Biochim Biophys Acta       Date:  2008-08-22

7.  Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease).

Authors:  B Otterbach; W Stoffel
Journal:  Cell       Date:  1995-06-30       Impact factor: 41.582

8.  Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration.

Authors:  Shannon L Macauley; Richard L Sidman; Edward H Schuchman; Tatyana Taksir; Gregory R Stewart
Journal:  Exp Neurol       Date:  2008-08-16       Impact factor: 5.330

9.  Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease.

Authors:  K Horinouchi; S Erlich; D P Perl; K Ferlinz; C L Bisgaier; K Sandhoff; R J Desnick; C L Stewart; E H Schuchman
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

10.  A fluorescent glycolipid-binding peptide probe traces cholesterol dependent microdomain-derived trafficking pathways.

Authors:  Steffen Steinert; Esther Lee; Guillaume Tresset; Dawei Zhang; Ralf Hortsch; Richard Wetzel; Sarita Hebbar; Jeyapriya Raja Sundram; Sashi Kesavapany; Elke Boschke; Rachel Kraut
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  36 in total

1.  Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism.

Authors:  Flavia Antonucci; Elena Turola; Loredana Riganti; Matteo Caleo; Martina Gabrielli; Cristiana Perrotta; Luisa Novellino; Emilio Clementi; Paola Giussani; Paola Viani; Michela Matteoli; Claudia Verderio
Journal:  EMBO J       Date:  2012-01-13       Impact factor: 11.598

2.  Systematic Genetic Analysis of the SMPD1 Gene in Chinese Patients with Parkinson's Disease.

Authors:  Sheng Deng; Xiong Deng; Zhi Song; Xiaofei Xiu; Yi Guo; Jingjing Xiao; Hao Deng
Journal:  Mol Neurobiol       Date:  2015-09-16       Impact factor: 5.590

Review 3.  Clinical application of ceramide in cancer treatment.

Authors:  Kazuki Moro; Masayuki Nagahashi; Emmanuel Gabriel; Kazuaki Takabe; Toshifumi Wakai
Journal:  Breast Cancer       Date:  2019-04-08       Impact factor: 4.239

Review 4.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

5.  Fat-fated microglial dysfunction.

Authors:  Aymeric Silvin; Florent Ginhoux
Journal:  EMBO J       Date:  2018-12-19       Impact factor: 11.598

Review 6.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

7.  Oligodendrocyte loss during the disease course in a canine model of the lysosomal storage disease fucosidosis.

Authors:  Jessica L Fletcher; Gauthami S Kondagari; Charles H Vite; Peter Williamson; Rosanne M Taylor
Journal:  J Neuropathol Exp Neurol       Date:  2014-06       Impact factor: 3.685

Review 8.  Sphingolipids in neurodegeneration (with focus on ceramide and S1P).

Authors:  Guanghu Wang; Erhard Bieberich
Journal:  Adv Biol Regul       Date:  2018-09-22

Review 9.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

Review 10.  Lipid rafts in neurodegeneration and neuroprotection.

Authors:  Sandro Sonnino; Massimo Aureli; Sara Grassi; Laura Mauri; Simona Prioni; Alessandro Prinetti
Journal:  Mol Neurobiol       Date:  2013-12-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.